Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Gene therapy may provide a cure for hemophilia and overcome the limitations of protein replacement therapy. Increasing the potency of gene transfer vectors may allow improvement of their therapeutic index, as lower doses can be administered to achieve therapeutic benefit, reducing toxicity of in vivo administration. Here we generated codon-usage optimized and hyperfunctional factor IX (FIX) transgenes carrying an R338L amino acid substitution (FIX Padua), previously associated with clotting hyperactivity and thrombophilia. We delivered these transgenes to hemophilia B mice by hepatocyte-targeted integration-competent and -defective lentiviral vectors. The hyperfunctional FIX transgenes increased FIX activity reconstituted in the plasma without detectable adverse effects, allowing correction of the disease phenotype at lower vector doses and resulting in improved hemostasis in vivo. The combined effect of codon optimization with the hyperactivating FIX-R338L mutation resulted in a robust 15-fold gain in potency and therefore provides a promising strategy to improve the efficacy, feasibility, and safety of hemophilia gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A similar study using FIX transgenes carrying an R338L amino acid substitution associated with clotting hyperactivity and thrombophilia showed increased gene therapy efficacy but also less efficiency in hepatic transgene expression of NILVs [136].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [136]
In the citing paper
“Modifications in the NAb recognition sites can enhance transduction efficiency [190–193].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [193]
In the citing paper
“Although AAV efforts predominate, lentiviral vectors for either systemic infusion157,158 or ex vivo transduction of hematopoietic stem cells159, 160, 161 or induced pluripotent stem cells162 are being pursued preclinically or as a phase I clinical trial.156”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [157]
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Understanding the contribution of synonymous mutations to human disease
Sauna, Z. E., & Kimchi-Sarfaty, C. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3051 · Cited by 1,022
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
D-dimer antigen: current concepts and future prospects
Adam, S. S., Key, N. S., & Greenberg, C. S. (2009) · Blood · doi:10.1182/blood-2008-06-165845 · Cited by 668
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Self-citationEffective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N. P., Finn, J. D., Spiezia, L., Radu, C., & Arruda, V. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904377 · Cited by 394
Recent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Self-citation
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“110,111 This approach will need to be carefully tested, particularly when nonnative transgene variants are expressed with vectors that may interact with the innate immune system (vide supra and Martino et al 34 and Wu et al 130 ).”
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
A new and updated resource for codon usage tables
Athey, J., Alexaki, A., Osipova, E., Rostovtsev, A., Santana-Quintero, L. V., Katneni, U., Simonyan, V., & Kimchi-Sarfaty, C. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1793-7 · Cited by 279
Clinical development of gene therapy: results and lessons from recent successes
Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.34 · Cited by 232
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Multiple studies reduced the therapeutic dose of AAV and utilized hyperactive variants of delivered transgene [88, 193, 230].”
Background
Metadata
- Authors
- Cantore, A., Nair, N., Della Valle, P., Di Matteo, M., Màtrai, J., Sanvito, F., Brombin, C., Di Serio, C., D'Angelo, A., Chuah, M., Naldini, L., & VandenDriessche, T.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Université Libre de Bruxelles (BE)
- Coagulation Service and Thrombosis Research Unit, San Raffaele Scientific Institute, Milan, Italy;
- Department of Gene Therapy and Regenerative Medicine, Free University of Brussels, Brussels, Belgium;
- IRCCS Ospedale San Raffaele (IT)
- University Center for Statistics in the Biomedical Sciences, Vita Salute San Raffaele University, Milan, Italy
- Corresponding author
- Cantore, Alessio
- Nair, Nisha
- Chuah, Marinee
- Naldini, Luigi
- VandenDriessche, Thierry
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-11-29
- Volume
- 120
- Issue
- 23
- Pages
- 4517-4520
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2063613634
- Cited by
- 101
- References
- 18
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 8 · 2020: 4 · 2019: 8 · 2018: 11 · 2017: 11 · 2016: 2 · 2015: 13 · 2014: 10 · 2013: 11 · 2012: 1
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- European Commission (222878)
- Fonds Wetenschappelijk Onderzoek
- Vrije Universiteit Brussel
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, gene therapy, coagulation factor IX, codon optimization, lentiviral vectors, transgenic mice, thrombophilia, hemostasis
- MeSH terms
- Animals, Blood Coagulation, Hemophilia B, Dogs, Factor IX, Feasibility Studies, Genetic Vectors, Humans, Mutation, Partial Thromboplastin Time, Genetic Therapy, Lentivirus, Treatment Outcome, Amino Acid Substitution, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. https://app.cochat.ai/papers/10.1182/blood-2012-05-432591
- The paper
- Cantore, A., Nair, N., Della Valle, P., Di Matteo, M., Màtrai, J., Sanvito, F., Brombin, C., Di Serio, C., D'Angelo, A., Chuah, M., Naldini, L., & VandenDriessche, T. (2012). Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood. https://doi.org/10.1182/blood-2012-05-432591
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.